50% Istituto Ortopedico Rizzoli; 50% Istituto Superiore di Sanità
The invention provides a human monoclonal antibody in single chain fragment variable (scFv) format that recognizes an extracellular epitope of the human CD99 determinant expressed on the cell surface of the Ewing sarcoma tumor cells. The antibody may be used to selectively distinguish EWST cells and may find application in differential diagnosis, or in diagnosis imaging. Due to its small molecular size, the antibody should provide for efficient tissue penetration, yet give rapid plasma clearance. In addition, the antibody has all the prerequisites to be further developed for therapeutic purposis, since the activation of CD99 is able to induce rapid apoptosis of Ewing sarcoma cells. The invention was the results of strict collaboration between Istituto Ortopedico Rizzoli and Istituto Superiore di Sanità.